epilepsy society
epilepsy society Company Information
Company Number
00492761
Next Accounts
Dec 2025
Shareholders
-
Group Structure
View All
Industry
Other human health activities
+1Registered Address
epilepsy society chesham lane, chalfont st peter, buckinghamshire, SL9 0RJ
epilepsy society Estimated Valuation
Pomanda estimates the enterprise value of EPILEPSY SOCIETY at £16.1m based on a Turnover of £18.9m and 0.86x industry multiple (adjusted for size and gross margin).
epilepsy society Estimated Valuation
Pomanda estimates the enterprise value of EPILEPSY SOCIETY at £0 based on an EBITDA of £-981.1k and a 6.97x industry multiple (adjusted for size and gross margin).
epilepsy society Estimated Valuation
Pomanda estimates the enterprise value of EPILEPSY SOCIETY at £67.9m based on Net Assets of £26.7m and 2.55x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Epilepsy Society Overview
Epilepsy Society is a live company located in buckinghamshire, SL9 0RJ with a Companies House number of 00492761. It operates in the other human health activities sector, SIC Code 86900. Founded in March 1951, it's largest shareholder is unknown. Epilepsy Society is a mature, mid sized company, Pomanda has estimated its turnover at £18.9m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Epilepsy Society Health Check
Pomanda's financial health check has awarded Epilepsy Society a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 5 areas for improvement. Company Health Check FAQs
6 Strong
1 Regular
5 Weak
Size
annual sales of £18.9m, make it larger than the average company (£2.8m)
£18.9m - Epilepsy Society
£2.8m - Industry AVG
Growth
3 year (CAGR) sales growth of 6%, show it is growing at a slower rate (7.3%)
6% - Epilepsy Society
7.3% - Industry AVG
Production
with a gross margin of 37.4%, this company has a comparable cost of product (37.4%)
37.4% - Epilepsy Society
37.4% - Industry AVG
Profitability
an operating margin of -8.9% make it less profitable than the average company (9.5%)
-8.9% - Epilepsy Society
9.5% - Industry AVG
Employees
with 319 employees, this is above the industry average (67)
319 - Epilepsy Society
67 - Industry AVG
Pay Structure
on an average salary of £32.7k, the company has a higher pay structure (£25.3k)
£32.7k - Epilepsy Society
£25.3k - Industry AVG
Efficiency
resulting in sales per employee of £59.1k, this is more efficient (£44.1k)
£59.1k - Epilepsy Society
£44.1k - Industry AVG
Debtor Days
it gets paid by customers after 11 days, this is earlier than average (19 days)
11 days - Epilepsy Society
19 days - Industry AVG
Creditor Days
its suppliers are paid after 12 days, this is quicker than average (18 days)
12 days - Epilepsy Society
18 days - Industry AVG
Stock Days
it holds stock equivalent to 0 days, this is less than average (7 days)
0 days - Epilepsy Society
7 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 52 weeks, this is less cash available to meet short term requirements (68 weeks)
52 weeks - Epilepsy Society
68 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 18.8%, this is a lower level of debt than the average (39.6%)
18.8% - Epilepsy Society
39.6% - Industry AVG
EPILEPSY SOCIETY financials
Epilepsy Society's latest turnover from March 2024 is £18.9 million and the company has net assets of £26.7 million. According to their latest financial statements, Epilepsy Society has 319 employees and maintains cash reserves of £2.4 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 18,860,000 | 17,899,000 | 16,675,000 | 15,956,000 | 17,154,000 | 28,014,000 | 17,174,000 | 17,056,000 | 16,992,000 | 16,389,000 | 19,884,000 | 16,837,000 | 17,081,000 | 18,874,000 | 17,904,000 |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | |||||||||||||||
| Operating Profit | |||||||||||||||
| Interest Payable | |||||||||||||||
| Interest Receivable | |||||||||||||||
| Pre-Tax Profit | -1,367,000 | -1,512,000 | -213,000 | 1,055,000 | -2,070,000 | 10,096,000 | 129,000 | 215,000 | -1,035,000 | -108,000 | 2,665,000 | 1,252,000 | 903,000 | 1,377,000 | 3,000 |
| Tax | |||||||||||||||
| Profit After Tax | -1,367,000 | -1,512,000 | -213,000 | 1,055,000 | -2,070,000 | 10,096,000 | 129,000 | 215,000 | -1,035,000 | -108,000 | 2,665,000 | 1,252,000 | 903,000 | 1,377,000 | 3,000 |
| Dividends Paid | |||||||||||||||
| Retained Profit | -1,367,000 | -1,512,000 | -213,000 | 1,055,000 | -2,070,000 | 10,096,000 | 129,000 | 215,000 | -1,035,000 | -108,000 | 2,665,000 | 1,252,000 | 903,000 | 1,377,000 | 3,000 |
| Employee Costs | 10,421,000 | 9,060,000 | 9,073,000 | 9,493,000 | 9,576,000 | 9,159,000 | 9,803,000 | 10,458,000 | 10,582,000 | 10,565,000 | 10,645,000 | 10,191,000 | 10,720,000 | 12,132,000 | 12,107,000 |
| Number Of Employees | 319 | 325 | 373 | 276 | 280 | 307 | 334 | 391 | 396 | 382 | 347 | 336 | 326 | 345 | 364 |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 14,824,000 | 14,661,000 | 14,969,000 | 15,474,000 | 16,114,000 | 16,575,000 | 46,102,000 | 46,997,000 | 47,939,000 | 48,916,000 | 24,603,000 | 31,016,000 | 30,275,000 | 30,005,000 | 27,374,000 |
| Intangible Assets | 43,000 | 80,000 | 92,000 | 125,000 | 1,000 | 12,000 | 37,000 | 77,000 | 112,000 | ||||||
| Investments & Other | 9,974,000 | 9,478,000 | 4,440,000 | 4,440,000 | 2,200,000 | 2,200,000 | 2,610,000 | 2,610,000 | 2,610,000 | 2,610,000 | 10,000 | 10,000 | 10,000 | 118,000 | |
| Debtors (Due After 1 year) | |||||||||||||||
| Total Fixed Assets | 24,841,000 | 24,219,000 | 19,501,000 | 20,039,000 | 18,314,000 | 18,776,000 | 48,724,000 | 49,644,000 | 50,626,000 | 51,638,000 | 24,603,000 | 31,026,000 | 30,285,000 | 30,015,000 | 27,492,000 |
| Stock & work in progress | 25,000 | 23,000 | 16,000 | 15,000 | 60,000 | 63,000 | 53,000 | 47,000 | 37,000 | 37,000 | 41,000 | 51,000 | 39,000 | 40,000 | 64,000 |
| Trade Debtors | 578,000 | 420,000 | 185,000 | 469,000 | 99,000 | 593,000 | 525,000 | 694,000 | 616,000 | 816,000 | 836,000 | 721,000 | |||
| Group Debtors | |||||||||||||||
| Misc Debtors | 1,817,000 | 1,201,000 | 1,837,000 | 1,234,000 | 887,000 | 545,000 | 575,000 | 1,262,000 | 556,000 | 982,000 | 636,000 | 833,000 | 300,000 | 372,000 | 430,000 |
| Cash | 2,424,000 | 9,124,000 | 16,252,000 | 16,330,000 | 18,675,000 | 20,340,000 | 9,032,000 | 7,352,000 | 6,786,000 | 5,482,000 | 6,062,000 | 3,372,000 | 2,535,000 | 2,386,000 | 4,197,000 |
| misc current assets | 3,143,000 | 869,000 | |||||||||||||
| total current assets | 7,987,000 | 11,637,000 | 18,105,000 | 17,764,000 | 20,091,000 | 21,047,000 | 10,253,000 | 9,186,000 | 8,073,000 | 7,117,000 | 6,739,000 | 4,256,000 | 3,690,000 | 3,634,000 | 5,412,000 |
| total assets | 32,828,000 | 35,856,000 | 37,606,000 | 37,803,000 | 38,405,000 | 39,823,000 | 58,977,000 | 58,830,000 | 58,699,000 | 58,755,000 | 31,342,000 | 35,282,000 | 33,975,000 | 33,649,000 | 32,904,000 |
| Bank overdraft | |||||||||||||||
| Bank loan | 32,000 | 48,000 | 48,000 | 48,000 | 41,000 | ||||||||||
| Trade Creditors | 401,000 | 689,000 | 531,000 | 314,000 | 989,000 | 516,000 | 1,128,000 | 1,068,000 | 1,140,000 | 782,000 | 974,000 | 989,000 | |||
| Group/Directors Accounts | 333,000 | 244,000 | |||||||||||||
| other short term finances | |||||||||||||||
| hp & lease commitments | 86,000 | 111,000 | 97,000 | 80,000 | 118,000 | 92,000 | 89,000 | ||||||||
| other current liabilities | 2,016,000 | 3,288,000 | 2,583,000 | 2,708,000 | 2,178,000 | 2,043,000 | 1,942,000 | 1,966,000 | 1,954,000 | 1,494,000 | 1,048,000 | 1,031,000 | 1,803,000 | 2,127,000 | 2,363,000 |
| total current liabilities | 2,417,000 | 3,977,000 | 3,114,000 | 3,022,000 | 3,618,000 | 2,962,000 | 3,215,000 | 3,162,000 | 3,253,000 | 2,368,000 | 2,111,000 | 2,020,000 | 1,803,000 | 2,127,000 | 2,363,000 |
| loans | 31,000 | 76,000 | 122,000 | 178,000 | 219,000 | 303,000 | 7,386,000 | 7,429,000 | 7,471,000 | 7,472,000 | |||||
| hp & lease commitments | 87,000 | 206,000 | 323,000 | 382,000 | 500,000 | 592,000 | |||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | |||||||||||||||
| total long term liabilities | 3,761,000 | 3,730,000 | 6,550,000 | 9,555,000 | 8,708,000 | 9,682,000 | 10,794,000 | 10,644,000 | 7,829,000 | 7,807,000 | 5,815,000 | 13,748,000 | 12,452,000 | 10,087,000 | 13,236,000 |
| total liabilities | 6,178,000 | 7,707,000 | 9,664,000 | 12,577,000 | 12,326,000 | 12,644,000 | 14,009,000 | 13,806,000 | 11,082,000 | 10,175,000 | 7,926,000 | 15,768,000 | 14,255,000 | 12,214,000 | 15,599,000 |
| net assets | 26,650,000 | 28,149,000 | 27,942,000 | 25,226,000 | 26,079,000 | 27,179,000 | 44,968,000 | 45,024,000 | 47,617,000 | 48,580,000 | 23,416,000 | 19,514,000 | 19,720,000 | 21,435,000 | 17,305,000 |
| total shareholders funds | 26,650,000 | 28,149,000 | 27,942,000 | 25,226,000 | 26,079,000 | 27,179,000 | 44,968,000 | 45,024,000 | 47,617,000 | 48,580,000 | 23,416,000 | 19,514,000 | 19,720,000 | 21,435,000 | 17,305,000 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | |||||||||||||||
| Depreciation | 648,000 | 609,000 | 612,000 | 711,000 | 710,000 | 732,000 | 1,015,000 | 1,003,000 | 1,077,000 | 782,000 | 919,000 | 853,000 | 862,000 | 950,000 | 780,000 |
| Amortisation | 41,000 | 38,000 | 33,000 | 23,000 | 1,000 | 11,000 | 27,000 | 40,000 | 37,000 | 37,000 | |||||
| Tax | |||||||||||||||
| Stock | 2,000 | 7,000 | 1,000 | -45,000 | -3,000 | 10,000 | 6,000 | 10,000 | -4,000 | -10,000 | 12,000 | -1,000 | -24,000 | 64,000 | |
| Debtors | 774,000 | -216,000 | 418,000 | 63,000 | 712,000 | -524,000 | -619,000 | 537,000 | -348,000 | 962,000 | -197,000 | -283,000 | -92,000 | 57,000 | 1,151,000 |
| Creditors | -288,000 | 158,000 | 217,000 | -675,000 | 473,000 | -612,000 | 60,000 | -72,000 | 358,000 | -192,000 | -15,000 | 989,000 | |||
| Accruals and Deferred Income | -1,272,000 | 705,000 | -125,000 | 530,000 | 135,000 | 101,000 | -24,000 | 12,000 | 460,000 | 446,000 | 17,000 | -772,000 | -324,000 | -236,000 | 2,363,000 |
| Deferred Taxes & Provisions | |||||||||||||||
| Cash flow from operations | |||||||||||||||
| Investing Activities | |||||||||||||||
| capital expenditure | 11,361,000 | -119,000 | -67,000 | -101,000 | -214,000 | 9,265,000 | -1,485,000 | -1,132,000 | -1,976,000 | -3,146,000 | |||||
| Change in Investments | 496,000 | 5,038,000 | 2,240,000 | -410,000 | 2,610,000 | -10,000 | -108,000 | 118,000 | |||||||
| cash flow from investments | -496,000 | -5,038,000 | -2,240,000 | 11,771,000 | -119,000 | -67,000 | -101,000 | -2,824,000 | 9,275,000 | -1,485,000 | -1,132,000 | -1,868,000 | -3,264,000 | ||
| Financing Activities | |||||||||||||||
| Bank loans | -32,000 | -16,000 | 7,000 | 41,000 | |||||||||||
| Group/Directors Accounts | -333,000 | 89,000 | 244,000 | ||||||||||||
| Other Short Term Loans | |||||||||||||||
| Long term loans | -31,000 | -45,000 | -46,000 | -56,000 | -41,000 | -84,000 | -7,083,000 | -43,000 | -42,000 | -1,000 | 7,472,000 | ||||
| Hire Purchase and Lease Commitments | -86,000 | -112,000 | -105,000 | -100,000 | -97,000 | -92,000 | -89,000 | 681,000 | |||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | |||||||||||||||
| cash flow from financing | -132,000 | 1,719,000 | 2,929,000 | -2,359,000 | 900,000 | -27,791,000 | -331,000 | -2,954,000 | -1,501,000 | -2,660,000 | 2,752,000 | 24,774,000 | |||
| cash and cash equivalents | |||||||||||||||
| cash | -6,700,000 | -7,128,000 | -78,000 | -2,345,000 | -1,665,000 | 11,308,000 | 1,680,000 | 566,000 | 1,304,000 | -580,000 | 2,690,000 | 837,000 | 149,000 | -1,811,000 | 4,197,000 |
| overdraft | |||||||||||||||
| change in cash | -6,700,000 | -7,128,000 | -78,000 | -2,345,000 | -1,665,000 | 11,308,000 | 1,680,000 | 566,000 | 1,304,000 | -580,000 | 2,690,000 | 837,000 | 149,000 | -1,811,000 | 4,197,000 |
epilepsy society Credit Report and Business Information
Epilepsy Society Competitor Analysis
Perform a competitor analysis for epilepsy society by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other mid companies, companies in SL9 area or any other competitors across 12 key performance metrics.
epilepsy society Ownership
EPILEPSY SOCIETY group structure
Epilepsy Society has 2 subsidiary companies.
Ultimate parent company
EPILEPSY SOCIETY
00492761
2 subsidiaries
epilepsy society directors
Epilepsy Society currently has 13 directors. The longest serving directors include Mr James Hagan (Nov 2015) and Mrs Catherine Alcock (Dec 2015).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr James Hagan | United Kingdom | 73 years | Nov 2015 | - | Director |
| Mrs Catherine Alcock | 67 years | Dec 2015 | - | Director | |
| Mr Andrew Gosling | 69 years | Dec 2021 | - | Director | |
| Mr Andrew Gray | United Kingdom | 61 years | Dec 2021 | - | Director |
| Ms Jacqueline Sullivan | United Kingdom | 66 years | Mar 2022 | - | Director |
| Ms Tracie Coultas-Pitman | United Kingdom | 53 years | Mar 2022 | - | Director |
| Mrs Rae Avatar Barnett | United Kingdom | 61 years | Dec 2023 | - | Director |
| Mrs Hannah Purves | United Kingdom | 51 years | Dec 2023 | - | Director |
| Dr Robin Woolfson | England | 66 years | Dec 2023 | - | Director |
| Mr Nikolas Grant | United Kingdom | 49 years | Dec 2023 | - | Director |
P&L
March 2024turnover
18.9m
+5%
operating profit
-1.7m
0%
gross margin
37.4%
+2.62%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
26.7m
-0.05%
total assets
32.8m
-0.08%
cash
2.4m
-0.73%
net assets
Total assets minus all liabilities
epilepsy society company details
company number
00492761
Type
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
86900 - Other human health activities
87100 - Residential nursing care activities
incorporation date
March 1951
age
74
incorporated
UK
ultimate parent company
accounts
Group
last accounts submitted
March 2024
previous names
national society for epilepsy(the) (March 2018)
national society for epileps (the) (December 1979)
accountant
-
auditor
CROWE UK LLP
address
epilepsy society chesham lane, chalfont st peter, buckinghamshire, SL9 0RJ
Bank
NATIONAL WESTMINSTER BANK PLC
Legal Advisor
-
epilepsy society Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 8 charges/mortgages relating to epilepsy society. Currently there are 0 open charges and 8 have been satisfied in the past.
epilepsy society Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for EPILEPSY SOCIETY. This can take several minutes, an email will notify you when this has completed.
epilepsy society Companies House Filings - See Documents
| date | description | view/download |
|---|
